517894-64-3

Basic information

• Product Name: 5-Formyl-3-methyl-1H-pyrrole-2,4-dicarboxylic acid 2-(1,1-dimethylethyl) 4-ethyl ester
• Synonyms: 2-tert-Butyl 4-ethyl 5-formyl-3-methyl-1H-pyrrole-2,4-dicarboxylate;5-Formyl-3-methyl-1H-pyrrole-2,4-dicarboxylic acid 2-(1,1-dimethylethyl) 4-ethyl ester
• CAS NO: 517894-64-3
• Molecular Formula: C14H19NO5
• Molecular Weight: 281.30436
• Mol File: 517894-64-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 120-121℃
• Appearance: /
• Density: 1.184
• CAS DataBase Reference: 5-Formyl-3-methyl-1H-pyrrole-2,4-dicarboxylic acid 2-(1,1-dimethylethyl) 4-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Formyl-3-methyl-1H-pyrrole-2,4-dicarboxylic acid 2-(1,1-dimethylethyl) 4-ethyl ester(517894-64-3)
• EPA Substance Registry System: 5-Formyl-3-methyl-1H-pyrrole-2,4-dicarboxylic acid 2-(1,1-dimethylethyl) 4-ethyl ester(517894-64-3)

Safety Data

• Hazardous Substances Data: 517894-64-3(Hazardous Substances Data)

Upstream product

• 86770-31-2 2-tert-butyl 4-ethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate 

Relevant articles and documents

Synthesis and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors

Signaling pathways of VEGFs and PDGFs are crucial in tumor angiogenesis, which is essential in solid tumor progression and metastasis. This study reports our strategy for designing and synthesizing a series of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors. The target compounds were obtained by condensation of 5-substituted oxindoles with N-substituted 2-pyrrolidone aldehyde 7 in satisfactory yields. Of these, 11 and 12 had the highest potency and, compared to sunitinib, showed: (1) significant increase in anti-proliferation of various cancer cells with a favorable selective index (SI); (2) higher inhibitory potency against both VEGFR-2 and PDGFRβ. The molecular modeling results showed that, in terms of VEGFR-2 binding, the synthesized products had a similar binding mode to sunitinib but with tighter interaction.

Synthesis method of henatinib intermediate and obtained henatinib intermediate

The invention discloses a synthesis method of a henatinib intermediate and the obtained henatinib intermediate. The preparation method comprises the following steps of: (1) adding 3, 5-dimethyl-1H-pyrrole-2, 4-dicarboxylic acid-2-tert-butyl-4-ethyl ester into an organic solvent, then adding ceric ammonium nitrate, and reacting at room temperature to obtain an intermediate 1; (2) under the protection of inert gas, adding the intermediate 1 into an organic solvent, then adding (benzyloxyethyl) phenylphosphine, and reacting at room temperature to obtain an intermediate 2; and (3) adding the intermediate 2 into methanol, then adding a palladium-carbon catalyst, introducing hydrogen, and fully reacting at 30-35 DEG C to obtain the henatinib intermediate. The method has few reaction steps, only comprises three steps of oxidation, Wittig reaction and hydrogenation, does not have a hydrolysis process, avoids the phenomenon of environmental unfriendliness caused by a large amount of acid water, does not have a reduction reaction process of an expensive reducing agent, and is simple to operate, high in yield, few in impurities and high in purity.

PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF

Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof are disclosed. More specifically, pharmaceutically acceptable salts of (R,Z)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-methylene)-5-(2-hydroxy-3-morpholinyl-4-yl-propyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azepin-4-one presented by formula (I), the preparation method and the use thereof as therapeutic agents, especially as protein kinase inhibitors, are disclosed.